Microbot Medical

Microbot Medical

MBOT
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

MBOT · Stock Price

USD 2.13-0.41 (-16.14%)
Market Cap: $141.7M

Historical price data

Overview

Microbot Medical is a commercial-stage innovator creating a new category of single-use, disposable surgical robotics. The company's flagship LIBERTY system is designed to break down cost and accessibility barriers in endovascular procedures, having secured initial hospital adoptions at prestigious institutions like Emory University Hospital and Tampa General Hospital. Its strategy centers on a capital-light, high-margin consumable model that leverages standard tools to drive rapid clinical adoption and redefine the future of minimally invasive intervention.

Peripheral Vascular DiseaseNeurovascular DiseaseCoronary Artery Disease

Technology Platform

The LIBERTY® Endovascular Robotic System is a single-use, disposable, and remotely operated robotic platform designed to perform minimally invasive vascular procedures using standard catheters and guidewires.

Opportunities

Microbot's single-use robotic model taps into a massive, underserved market of hospitals unable to afford traditional multi-million dollar systems.
The growing volume of endovascular procedures and healthcare's shift towards operational expenditure models create powerful tailwinds for its disposable, pay-per-procedure solution.

Risk Factors

Key risks include commercial execution as the company transitions from development to sales, securing timely FDA clearance, potential future dilution from capital raises, and the challenge of educating the market on a novel economic model while incumbents may develop competing offerings.

Competitive Landscape

Microbot avoids direct competition with giants like Intuitive Surgical by creating a new category of disposable robotics. Its primary competition is the high-cost economic model itself, though it faces established vascular robotics players like Siemens/Corindus which utilize traditional capital sales.